ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: As aforementioned, PI3K/mTOR signaling is hyperactive in CML, and investigation of potential synergy between MTIs and TKIs targeting mutant ABL1 (e.g., imatinib, dasatinib) in CML is planned (NCT01188889) (39).